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Running title: Prediction of Alzheimer’s disease risk 
Abstract 
Background: The identification of subjects at high risk for Alzheimer’s disease is important 
for prognosis and early intervention. We investigated the polygenic architecture of 
Alzheimer’s disease (AD) and the accuracy of AD prediction models, including and 
excluding the polygenic component in the model. 
Methods: This study used genotype data from the powerful dataset comprising 17,008 cases 
and 37,154 controls obtained from the International Genomics of Alzheimer’s Project 
(IGAP). Polygenic score analysis tested whether the alleles identified to associate with 
disease in one sample set were significantly enriched in the cases relative to the controls in an 
independent sample. The disease prediction accuracy was investigated by means of 
sensitivity, specificity, Area Under the receiver operating characteristic Curve (AUC) and 
positive predictive value (PPV). 
Results: We observed significant evidence for a polygenic component enriched in 
Alzheimer’s disease (p=4.9x10-26). This enrichment remained significant after APOE and 
other genome-wide associated regions were excluded (p=3.4x10
-19
). The best prediction 
accuracy AUC=78% was achieved by a logistic regression model with APOE, the polygenic 
score as predictors and age. When looking at the genetic component only, the PPV was 81%, 
increasing to 82% when age was added as a predictor. Setting the total normalised polygenic 
score of greater than 0.91, the positive predictive value has reached 90%. 
Conclusion: Polygenic score has strong predictive utility of Alzheimer’s disease risk and is a 
valuable research tool in experimental designs, e.g. for selecting Alzheimer’s disease patients 
into clinical trials. 
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Introduction 
Genome-wide association (GWA) studies have proved a powerful method to identify 
susceptibility alleles for complex diseases. The most powerful currently undertaken study, 
provided by the International Genomics of Alzheimer’s Project (IGAP), has identified over 
twenty AD susceptibility loci (Lambert et al., 2013). GWA study datasets can be used to 
determine a polygenic contribution of common SNPs that show disease association but fail to 
meet the accepted P-value threshold for genome-wide significance (p<5x10
-8
). Recent studies 
confirm that the estimated heritability detected in AD GWA studies (24-35%) (Lee et al., 
2013) increases substantially when weak effect loci are also considered. This strongly implies 
that a large proportion of the genetic signal must lie below the genome wide significance 
threshold. 
 
The Polygenic score (PS) approach encompasses more of the causal variance, as a genetic 
risk score is calculated based not solely on genome-wide significant polymorphisms, but on 
all nominally associated variants at a defined significance threshold (typically thousands of 
variants). This type of analysis has recently shown significant polygenic contribution in other 
complex genetic diseases. For example in Parkinson disease, a polygenic basis was confirmed 
and shown to correlate with age at disease onset (Escott-Price et al., 2014). The method can 
also be used to identify overlap in genetic determinants between related disorders, e.g. 
schizophrenia and bipolar disorder; depression and anxiety (Demirkan et al., 2011). While 
the polygenic method undoubtedly introduces noise by including some variants that are not 
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involved in disease susceptibility (i.e. false positives), this is more than offset by the 
increased power to identify those at highest/lowest risk of disease. Trait differences between 
those with highest/lowest polygenic risk scores have also been identified. For example, in a 
study of the Lothian Birth Cohort, increased polygenic risk of schizophrenia was associated 
with lower cognitive ability at age 70 and greater relative decline in general cognitive ability 
between the ages of 11 and 70 (McIntosh et al., 2013).  
 
We investigated the polygenic architecture of Alzheimer’s disease using the powerful IGAP 
GWA dataset (Lambert et al., 2013). The IGAP dataset was split into two independent 
subsets before the polygenic contribution to AD was investigated by assessing whether score 
alleles identified in one subset were significantly enriched in cases from another subset.  
 
We also investigated the prediction accuracy of the model, which includes the number of 4 
and 2 alleles at the APOE gene, a PS component based upon genome-wide significant 
(GWS) loci, and a PS component constructed using all independent markers within the 
dataset including statistically not-significant SNPs.  Furthermore we looked at the utility of 
the PS when the analysis was restricted to subjects with 2 and 3 alleles only. As age is a 
strong predictor of AD, we tested the prediction models in samples stratified by age. To test 
the sensitivity of the prediction models to population differences we ran the same analyses for 
subjects from UK, USA and Germany separately. 
 
Materials and Methods 
We used the discovery dataset reported by the IGAP consortium (Lambert et al., 2013) , 
comprising of 17,008 AD cases and 37,154 controls. This sample of AD cases and controls 
comprises 4 data sets taken from GWA studies performed by GERAD, EADI, CHARGE and 
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ADGC (Lambert et al., 2013). Full details of each study including the samples and methods 
utilised are provided elsewhere (Harold et al., 2009, Lambert et al., 2009, Seshadri et al., 
2010, Hollingworth et al., 2011, Naj et al., 2011). Each of the 4 datasets were imputed with 
either Impute2(Howie et al., 2009) or MACH(Li et al., 2010) software, using the 1000 
genomes data (release Dec2010) as a reference panel. 
 
Polygenic score analysis 
We followed the approach previously described by the International Schizophrenia 
Consortium (International Schizophrenia et al., 2009). The PS analysis requires two 
independent datasets. For the first, result data is sufficient as this dataset is used to select the 
SNPs, the risk score alleles and their genetic effects. The second dataset is used to test 
whether the polygenic risk scores differ in cases and controls and requires the genotypes for 
each individual. The meta-analysed results data of the EADI, CHARGE and ADGC consortia 
(13,831 cases and 29,877 controls, hereafter referred to as IGAP.noGERAD) was used for 
SNP selection. We used the individual genotypes of the GERAD consortium (Harold et al., 
2009) data (3,177 cases and 7,277 controls), we used the GERAD data as the test sample. 
We included only autosomal SNPs that passed stringent quality control criteria, i.e. minor 
allele frequencies (MAF) ≥0.01 and imputation quality score greater than or equal to 0.5 in 
each study. This resulted in 6,928,531 SNPs, which were present in at least 40% of the AD 
cases and 40% of the controls, being included in the analysis. The summary statistics across 
the 3 datasets were combined using fixed-effects inverse variance-weighted meta-analysis.  
Using GERAD study data we performed a) random linkage disequilibrium (LD) pruning 
using r
2
>0.2, and b) “intelligent” pruning (--clump option in PLINK (Purcell et al., 2007) 
6 
 
genetic analysis tool) using the same r
2
 parameter and a physical distance threshold for 
clumping SNPs of 1Mb. The random LD pruning resulted in 401,584 SNPs that are in 
relative linkage equilibrium (r
2≤0.2) and common between GERAD and IGAP.noGERAD 
datasets. The “intelligent” pruning allows to capture SNPs which are most (even if not-
significantly) associated with the disease in an LD block. This “intelligent” pruning identified 
538,363 independent SNPs that were most significantly associated with AD in 
IGAP.noGERAD data. We selected markers, based upon significance thresholds, to construct 
a polygenic score in the GERAD data. The PS was calculated from the effect size (β)-
weighted sum of associated alleles within each subject. PS were normalised by subtracting 
the mean and dividing by the standard deviation.  
We assessed a variety of significance thresholds for the selection of markers for PS 
construction; overlapping panels of markers were used (e.g. significant at p≤0.01, 0.05, 0.1, 
…, 1 in the IGAP.noGERAD) in the construction of a subject-level score in GERAD 
case/control sample. The ability of each panel-based score distribution to distinguish those 
with disease from cognitively normal individuals was assessed using logistic regression 
analysis while adjusting for three principal components (Harold et al., 2009), reflecting 
underlying stratification in the sample due to population and/or genotyping technique 
differences. Age was not included as a covariate in the logistic regression models as it had 
already been accounted for as a covariate in the IGAP.noGERAD meta-analyses. 
 
Analysis of predictive accuracy 
To find the best predictors of the AD, we tested a variety of regression models. For this 
analysis we used the genotyped (rather than imputed) SNP data as we note that the prediction 
7 
 
accuracy is sensitive to the number of missing genotypes, which is often exacerbated by the 
uncertainty of imputation.  
Since the genotyped data at the APOE locus contained only proxy SNPs for the APOE-4 and 
APOE-2 variants (rs429358 and rs7412), we limited our analysis to those individuals (3,049 
cases and 1,554 controls) for whom we had APOE genotype data. For the other 21 GWS 
SNPs (Lambert et al., 2013), proxies with r
2
 greater than 0.8 were available for 11 SNPs in 
the GERAD data, for an additional 7 loci we had genotyped markers that were in modest LD 
(r
2
 between 0.5 and 0.8) with a GWS marker. Two GWS SNPs in the SLC24A4/RIN3 and 
CD33 loci had proxies with r
2
~0.3 (Supplementary Table 1). We excluded the DSG2 gene as 
this association did not replicate in IGAP stage 2(Lambert et al., 2013), and the best proxy to 
the putative GWS SNP was in low LD (r
2
=0.06) in the GERAD sample. 
We calculated sensitivity, specificity, area under the receiver operating characteristic curve 
(AUC) and positive and negative  predictive values (PPV and NPV) by comparing the 
observed case/control status and the predicted probability estimated by logistic regression 
models using the prediction() and performance() functions in R-statistical software. We used 
as predictors a number of explanatory variables including APOE-4, APOE-2, age, PS based 
upon 20 GWS SNP proxies, and PS calculated using SNPs with AD association p-values 
ranging from 0.0001 till 0.9 in the IGAP.noGERAD sample (APOE and GWAS loci were 
excluded, see Supplementary Table 1). We performed similar analyses on imputed data 
however the prediction accuracy using this dataset was marginally lower due to noise 
introduced through a number of missing values as a result of genotypes imputed with low 
certainty (results are not shown). To test the sensitivity of our results to possible bias due to 
age and population stratification, we ran the same models in subsamples stratified by 
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geographical region (UK, USA and Germany), and age groups <60, 60-69, 70-79, 80-89 and 
90+. 
 
Results 
Polygenic risk score analysis 
In this study we investigated whether the PS alleles identified in one AD GWA study were 
significantly enriched in the cases relative to the controls of an independent AD dataset. Our 
analysis revealed significant evidence for an overall enrichment of the AD polygenic risk 
score alleles of the IGAP.noGEARD data in the independent GEARD (Harold et al., 2009) 
cohort of 3,177 AD cases and 7,277 controls from the UK, Europe and USA (Table 1). The 
pattern of the PS association was similar to those seen in studies of other complex diseases 
shown to have a polygenic signal (International Schizophrenia et al., 2009, Stergiakouli et al., 
2012, Heilmann et al., 2013, Michailidou et al., 2013). Our most significant evidence for 
association was observed when SNPs with a selection threshold (PT) of p≤0.5 in the 
IGAP.noGERAD sample were included. The p-values for a significant enrichment in the 
polygenic score ranged from 3.9x10
-20
 to 4.9x10
-26
 dependent on the PT used (Table 1). For 
all significant associations the B-coefficients were positive, indicating that a higher polygenic 
score in the IGAP.noGERAD discovery dataset corresponds to a higher score in the 
independent GERAD replication dataset and provides evidence for a polygenic contribution 
to the development of Alzheimer’s disease.  
Since the 538,363 independent SNPs that we used to identify AD polygenic risk score alleles 
included those most significantly associated with the disease, it is plausible that our results 
are artificially biased by SNPs whose evidence for association is a consequence of LD with a 
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known genome-wide significant SNPs. To investigate this possibility we repeated our 
analysis using identical analysis thresholds but excluding all 5,006 SNPs that, after LD 
pruning, were present at the 24 genomic regions previously reported to be strongly associated 
with AD (Lambert et al., 2013, Escott-Price et al., 2014). The regions were defined as 
±500KB of both sides of the GWA SNPs (Lambert et al., 2013) or GWA genes (Escott-Price 
et al., 2014) and between 44,400KB-46,500KB on chromosome 19 for the APOE locus 
(Supplementary Table 1). Given that each of these excluded regions is likely to contain at 
least one true AD susceptibility allele, this approach is highly conservative. Nevertheless, this 
analysis again revealed significant evidence that individuals with higher polygenic risk scores 
had greater probability of AD, with our most significant result p=3.4x10
-19
 (Table 2).  
Moreover, we obtained analogous results when we used an alternative method of LD pruning, 
which ignores the strength to which SNPs are associated with AD, and thus excludes SNPs 
from the 24 associated regions (Supplementary Table 2). These analyses suggest that our 
findings are not dependent on either the previously identified susceptibility loci or the SNPs 
that are associated with AD merely as a consequence of LD with the GWS loci. 
 
Analysis of predictive accuracy 
The identification of subjects at high risk for Alzheimer’s disease is important for prognosis 
and early intervention. We used logistic regression analysis to establish predictive values 
(sensitivity, specificity, AUC, PPV, NPV) of genetic risk factors in GERAD data. The results 
of this analysis are summarised in Table 3. A highly significant (p<10
-94
) overall outcome 
was obtained for all measures of predictive accuracy (Table 3). The APOE-4 allele is the 
strongest known genetic risk factor for AD. In the presence of APOE-4 alleles, the 
sensitivity was 0.59, the specificity 0.75 and the AUC=0.678. Inclusion of the numbers of 
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APOE-2 alleles in the logistic regression model slightly increases all prediction accuracy 
values, in particular, the AUC increased to 0.688. As expected, prediction accuracy was 
further enhanced (AUC=0.715) when we added the polygenic score variable based upon 
proxies for the 20 GWS SNPs, where the weights of the SNP risk alleles were identified from 
the independent dataset IGAP.noGERAD (Supplementary Figure 1) .  
We further investigated whether the PS based on risk alleles of small effect identified in one 
study (IGAP.noGERAD) were improving the prediction accuracy in an independent dataset 
(GERAD). For this we used PS calculated excluding the known AD associated regions 
(Supplementary Table 2). The best prediction accuracy (AUC=0.75) was achieved when we 
included the PS for SNPs with AD association p-values<0.5. The values of sensitivity and 
specificity (the proportion of cases and controls, respectively, which were correctly 
predicted) were about 0.69 when estimated with the minimized difference threshold 
MDT=0.64 (see Supplemental Figure 2).  If we reduce the probability threshold to 0.47, the 
percentage of correctly identified cases increases to 0.9, at a cost of specificity (0.35) (see 
Supplemental Figure 2). To investigate possible population differences in the prediction of 
AD risk, we looked at UK, German and USA subjects separately. The pattern of predictive 
modelling results was similar to the main analyses results in all strata (Supplementary Table 
3). Interestingly, the prediction in the USA strata was extremely good (the best 
AUC=0.95%). This might be due to the fact that the majority of subjects (about 80%) in the 
training set were of USA origin in contrast to 17% in the test set. 
Another way to look at the utility of the PS as a predictor for AD, is to exclude the strongest 
predictor, namely the 4 allele, from the analysis. There were 1242 cases and 1160 controls in 
the sample without 4 allele. When looking at these individuals only, the AUC was 65.0% 
when we included the PSs based upon proxies for the 20 GWS SNPs and for SNPs with AD 
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association p-values<0.5, increasing to 65.8% when the number of 2 alleles was added as a 
predictor. Similar accuracy was achieved (64.5% and 65.8%) when we ran the analysis on the 
whole sample without 4 as a predictor. 
As expected, our results show that inclusion of age in the regression model further improved 
the prediction accuracy (AUC=0.78), see Table 3 and Supplementary Figure 2. In the context 
of practical application, e.g. in experimental designs comparing cases with high or low 
polygenic risk AD, age has to be taken into account. Supplementary Table 4 presents the 
results of the genetic predictive modelling stratified by age groups.  The results of the 
stratified analyses have shown similar pattern of prediction accuracy. As before, the best 
accuracy in each strata was achieved when the numbers of APOE-4, APOE-2 alleles, the 
PS variable based upon proxies for the 20 GWS SNPs, and the PS for SNPs with AD 
association p-values<0.5 were included as predictors. The AUC value was ranging from 73% 
to 79%, with the highest in the 60-69 age group (Supplementary Table 4). The best prediction 
in this age group might indicate that this particular age group has the strongest common 
genetic effect, with the younger age group (<60) potentially due to Mendelian forms of the 
disorder, and the older age groups confounded by general ageing effects.  
With regard to the practical use of PS in the identification of subjects at high risk for AD, we 
investigated the prediction accuracy of the genetic component in terms of positive predictive 
value (PPV), the percentage of patients with a positive prediction who actually have the 
disease. To achieve PPV of 0.9, i.e. have 90% of predicted cases to actually be cases, the 
prediction probability threshold has to be set to 0.87. This prediction probability threshold 
captured cases with normalised total PS of greater than 0.91. The total PS combines effects of 
4, 2, 20 GWAS proxy SNPs and AD associated SNPs (p<0.5), which comprised the best 
prediction model in our analysis. 
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Discussion 
The molecular genetic data reported in this study provides strong support for a large 
polygenic contribution to the overall heritable risk of Alzheimer’s disease. This implies that 
the genetic architecture of AD includes many common variants of small effect that is likely to 
reflect a large number of susceptibility genes and a complex set of biological pathways 
related to disease. The AD PS alleles identified in the GERAD cohort are not significantly 
enriched (minimum p=0.14) in an independent GWA study for Parkinson’s disease 
(Moskvina et al., 2013) indicating that the identified polygenic component of AD is disease 
specific.  
Further studies are required if we are to progress from the knowledge that there is a polygenic 
contribution to AD, to understanding the specific genetic factors that comprise the polygenic 
component. Increasing the discovery sample size will allow more loci with increasingly small 
individual effect sizes to pass the threshold of genome-wide significance, and should 
substantially refine the polygenic scores derived here. Moreover, as we have previously 
shown, using approaches such as gene pathways analyses it is possible to utilise the captured 
polygenic signal and identify genes or biological systems relevant to AD (International 
Genomics of Alzheimer's Disease, 2014).  
It is possible that our findings are influenced by rare AD susceptibility variants that are in LD 
with the common alleles analysed in this study. The ongoing efforts of studies performing 
exome and whole genome sequencing in large numbers of AD case/control cohorts will allow 
us to establish the haplotype structure of common and rare alleles an in turn, to understand 
which loci are subject to ‘synthetic association’(Dickson et al., 2010). Moreover, as 
previously demonstrated in other complex diseases (Purcell et al., 2014), future PS analysis 
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of variants identified by exome/genome sequencing are expected to further inform our 
understanding of the genetic underpinnings of AD. 
One possible limitation of this study that the population structure in the training set is only 
moderately representative of the test set, due to differences in proportions of subjects from 
different countries.  
In conclusion, the derived polygenic scores have demonstrated utility for calculating an 
individual level genetic risk profile that can predict disease development. Measures of 
polygenic burden could prove useful in distinguishing AD patients whose disease liability is 
most likely to carry a large or small genetic component. This utility of the developed 
polygenic score is increased among subjects of 60-69 years of age, which is a desirable target 
group for identification and preventative intervention of AD. Identifying these individuals 
would benefit study recruitment into clinical trials and could facilitate a better understanding 
of how gene-gene and gene-environment interactions increase risk for AD.  
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Table 1. Results of polygenic score analysis based upon a set of independent SNPs (at r
2≤0.2) 
pruned to retain those most significantly associated with the disease. 
PT* Effect SE p R
2
 NSNPs 
0.01 0.283 0.0308 3.9E-20 0.016 16,749 
0.05 0.311 0.0308 5.9E-24 0.019 61,552 
0.1 0.321 0.0309 2.6E-25 0.020 107,834 
0.2 0.327 0.0309 3.6E-26 0.021 185,737 
0.3 0.317 0.0308 7.9E-25 0.020 251,850 
0.4 0.323 0.0308 1.0E-25 0.020 308,780 
0.5 0.327 0.0310 4.9E-26 0.021 359,500 
0.6 0.326 0.0310 6.2E-26 0.021 404,626 
0.7 0.325 0.0309 9.3E-26 0.020 444,663 
0.8 0.328 0.0310 4.1E-26 0.021 480,271 
0.9 0.323 0.0309 1.9E-25 0.020 511,297 
1 0.321 0.0309 3.0E-25 0.020 538,362 
  
*Selection threshold of ‘score’ SNPs taken from the IGAP.noGERAD discovery sample. 
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Table 2. Results of polygenic score analysis based upon a set of relatively independent SNPs 
(at r
2≤0.2) pruned to retain those most significantly associated with the disease, excluding the 
genome-wide associated loci. (Exact positions of the excluded regions are given in 
Supplementary Table 1.) 
 
PT* Effect SE p R
2
 NSNPs 
0.01 0.154 0.0304 4.01x10
-7
 0.005 16,412 
0.05 0.232 0.0305 2.50x10
-14
 0.011 60,750 
0.1 0.256 0.0307 5.92x10
-17
 0.013 106,587 
0.2 0.270 0.0307 1.23x10
-18
 0.014 183,808 
0.3 0.263 0.0305 6.47x10
-18
 0.014 249,314 
0.4 0.271 0.0306 7.26x10
-19
 0.014 305,741 
0.5 0.275 0.0307 3.45x10
-19
 0.015 356,033 
0.6 0.274 0.0307 4.66x10
-19
 0.015 400,785 
0.7 0.273 0.0307 6.76x10
-19
 0.014 440,473 
0.8 0.276 0.0308 2.93x10
-19
 0.015 475,769 
0.9 0.271 0.0307 1.13x10
-18
 0.014 506,532 
1 0.269 0.0307 1.67x10
-18
 0.014 533,356 
  
*Selection threshold of ‘score’ SNPs taken from the IGAP.noGERAD discovery sample. 
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Table 3. Predictive accuracy for 3,049 AD cases vs 1,554 controls. The PS’ were constructed using independent SNPs associated with AD in 
IGAP.noGERAD at different significance levels (MODEL column), excluding APOE and 20 GWAS regions (see Supplementary Table 2). 
Numbers of SNPs participating in the predictive model are given in column N SNPs. 
MODEL N SNPs Sensitivity Specificity AUC PPV* NPV** 
4 1 0.593 0.746 0.678 0.821 0.483 
4 + 2 2 0.593 0.746 0.688 0.821 0.483 
4 + 2+ 20 GWAS SNPs + PS p<0.0001 130 0.669 0.669 0.717 0.798 0.507 
4 + 2+ 20 GWAS SNPs + PS p<0.001 549 0.668 0.668 0.720 0.798 0.506 
4 + 2+ 20 GWAS SNPs + PS p<0.01 3388 0.672 0.672 0.729 0.801 0.511 
4 + 2+ 20 GWAS SNPs + PS p<0.05 13273 0.677 0.677 0.738 0.804 0.516 
4 + 2+ 20 GWAS SNPs + PS p<0.1 23676 0.682 0.682 0.740 0.808 0.522 
4 + 2+ 20 GWAS SNPs + PS p<0.2 42273 0.683 0.683 0.743 0.808 0.523 
4 + 2+ 20 GWAS SNPs + PS p<0.3 58963 0.684 0.683 0.744 0.809 0.524 
4 + 2+ 20 GWAS SNPs + PS p<0.4 73941 0.684 0.684 0.744 0.809 0.525 
4 + 2+ 20 GWAS SNPs + PS p<0.5 87605 0.686 0.686 0.745 0.811 0.527 
4 + 2+ 20 GWAS SNPs + PS p<0.6 99724 0.685 0.685 0.745 0.810 0.526 
4 + 2+ 20 GWAS SNPs + PS p<0.7 110431 0.685 0.685 0.745 0.810 0.525 
4 + 2+ 20 GWAS SNPs + PS p<0.8 119616 0.683 0.683 0.745 0.809 0.523 
4 + 2+ 20 GWAS SNPs + PS p<0.9 127585 0.684 0.684 0.745 0.809 0.524 
4 + 2+ 20 GWAS SNPs + PS p<0.5+age 87605 0.702 0.701 0.781 0.822 0.545 
 
* Positive Predictive Value 
** Negative Predictive Value
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Supplemental Figure 1. ROC curves for predictive models with different predictors for risk of 
Alzheimer’s disease. 
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Supplemental Figure 2. Sensitivity-Specificity plot for the best predictive model which 
includes e4, e2, the polygenic score variable based upon proxies for the 20 GWS SNPs and 
the PS for SNPs with AD association p-values<0.5. 
 
